Brenig Therapeutics Inc. has disclosed leucine-rich repeat kinase 2 (LRRK2; dardarin) inhibitors reported to be useful for the treatment of Parkinson’s disease, among others.

Whanin Pharmaceutical Co. Ltd. has disclosed macrocyclic pyrimidine derivatives acting as...

Medshine Discovery Inc. has divulged azaspiro compounds acting as leucine-rich repeat kinase 2 (LRRK2; dardarin) inhibitors reported to be useful for the treatment of Parkinson’s disease.

H. Lundbeck A/S and Vernalis (R&D) Ltd. have jointly patented leucine-rich repeat kinase 2 (LRRK2; Dardarin) and/or LRRK2 mutant inhibitors reported to be useful for the treatment of Lewy body dementia, multiple system atrophy and Parkinson’s disease.

Leucine-rich repeat kinase 2 (LRRK2; Dardarin) inhibitors have been detailed in a recent Merck Sharp & Dohme Corp. patent and reported to be useful for the treatment of Parkinson’s disease, among others.

Sanofi SA has divulged substituted pyrrolo[2,3-d]pyrimidines acting as leucine-rich repeat kinase 2 (LRRK2; dardarin and/or G2019S mutant) inhibitors reported to be useful for the treatment of Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, Lewy body dementia, progressive supranuclear palsy, frontotemporal dementia and Niemann-Pick disease.

Standigm Inc. has disclosed leucine-rich repeat kinase 2 (LRRK2), particularly LRRK2 G2019S mutant, inhibitors reported to be useful for the treatment of cancer, neurodegeneration, rheumatoid arthritis, tuberculosis, axial spondyloarthritis, radiographic (ankylosing spondylitis), Crohn's disease and dyskinesia.

Standigm Inc. has identified new phenylaminopyrimidine leucine-rich repeat kinase 2 (LRRK2; Dardarin) (G2019S mutant) inhibitors reported to be useful for the treatment neurodegeneration, among other disorders.